Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI305 in advanced or recurrent non-squamous NSCLC
NCT02954172Phase 3Completed
- Sponsor
- Innovent Biologics
- Start
- Nov 2016
- Primary completion
- Oct 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of IBI305 in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Innovent Biologics. Primary endpoint: Objective Response Rate at 18 weeks. Started Nov 2016; status: completed.
02
Drugs
IBI305
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02954172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02954172.